This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PTK/ZK, PTK787/ZK222584
Description: PTK/ZK is an oral angiogenesis inhibitor that blocks all known VEGF receptor tyrosine kinases, which play a significant role in tumor angiogenesis, tumor growth, and metastases.
Deal Structure: In January 2005, Novartis announced that it has executed a commercialization agreement with Schering AG for PTK787. Novartis and Schering AG have been jointly researching and co-developing this compound since 1995. Under the commercialization agreement, the companies will partner on promotion and further development of the product in all oncology indications including metastatic colorectal cancer in all major markets. The value of the agreement to Schering and Novartis is designed to be equalbased on the co-promotion terms and territory allocations. Novartis will lead North Americanco-promotion activities and Schering will lead European co-promotion activities with both companies sharing co-promotion activities equally in Japan. Novartis will exclusively promote the product in Asia (excluding Japan) and Middle East. Schering will exclusively promote PTK787 in Latin America, Africa and Australia.
In a separate agreement with Schering, Novartis has obtained exclusive rights to...See full deal structure in Biomedtracker
Partners: Bayer AG
Additional information available to subscribers only: